Skip to main content
Publish date:

Sepracor's Brovana Cleared

The drug treats airways that have been constricted by chronic obstructive pulmonary disease.

Regulators have given their blessing to Brovana, a drug from

Sepracor

(SEPR)

that treats airways that have been constricted because of chronic obstructive pulmonary disease.

TheStreet Recommends

The drug is a long-acting solution meant to be used with a nebulizer, a device that converts liquid into a fine mist. The Food and Drug Administration approval was announced late Friday.

Following the regulatory clearance, shares of Sepracor were up 97 cents, or 2%, to $51.17 Monday.

"The approval of Brovana adds another important treatment option to Sepracor's respiratory franchise," said Sepracor President and Chief Operating Officer W. James O'Shea in a company press release.

O'Shea expects the drug to go on sale in the second quarter of 2007.

Chronic obstructive pulmonary disease, or COPD, is a lung disease that includes two main illnesses, chronic bronchitis and emphysema. Smoking is the primary cause.